3(top 5%)
Impact Factor
3.3(top 5%)
extended IF
72(top 5%)
citing journals
citing authors

Most Cited Articles of Clinical Breast Cancer

HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues2004504
Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer2009424
The global breast cancer burden: variations in epidemiology and survival2005346
Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design2009303
Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab2005296
TAILORx: trial assigning individualized options for treatment (Rx)2006217
Insulin-lowering effects of metformin in women with early breast cancer2008191
Cognitive training for improving executive function in chemotherapy-treated breast cancer survivors2013179
Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results2009174
Stress Management and Resilience Training (SMART) program to decrease stress and enhance resilience among breast cancer survivors: a pilot randomized clinical trial2011169
Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes2007144
Classification, Treatment Strategy, and Associated Drug Resistance in Breast Cancer2016142
Molecular mechanisms of breast cancer metastases to bone2005139
Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial2002135
Metastasis suppressor genes: basic biology and potential clinical use2003130
Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients2002127
The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial2010119
Results of a diet/exercise feasibility trial to prevent adverse body composition change in breast cancer patients on adjuvant chemotherapy2008119
Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer2008118
Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 9832522005118
Breast cancer chemotherapy-related cognitive dysfunction2002116
Circulating Tumor Cells in Metastatic Breast Cancer: Biologic Staging Beyond Tumor Burden2007115
Peripheral neuropathy with microtubule-targeting agents: occurrence and management approach2011114
Incidence and patterns of distant metastases for patients with early-stage breast cancer after breast conservation treatment2013113
Mammalian target of rapamycin: a new molecular target for breast cancer2003111